Is Illumina (ILMN) Fully Valued After Its 30% Monthly Rally?

Illumina (ILMN) has drawn fresh attention after a strong recent share move, with the stock up 7.1% in a day and about 30% over the past month.

Short-term momentum around Illumina is strong, with a 30-day share price return of 30.2% helping lift the year-to-date gain to 82.5%. The 1-year total shareholder return of 138.0% contrasts with a 5-year total shareholder return that is still down 41.8%.

Scan beyond Illumina's surge and explore other fast-moving opportunities with our curated list of 16 high quality undiscovered gems that are still flying under most investors' radar.

Illumina has already delivered a sharp rebound, yet the 5-year return is still down 41.8%. Has the recent surge simply closed the gap, or does the current valuation still leave meaningful upside on the table?

Most Popular Narrative: 23% Overvalued

Illumina's most followed valuation story places fair value at $199.63 using an 8.15% discount rate, compared with the latest close at $245.18. The recent rally now sits above that narrative anchor and puts more weight on whether the growth thesis can fully support the current price.

Operational efficiencies, disciplined cost controls, and targeted share repurchases have already resulted in notable operating margin and EPS improvements. Further scaling, along with tax headwinds turning into tailwinds, sets the stage for continued net margin and earnings growth over the next several years.

See why 49 investors see Illumina as 23% overvalued.

Result: Fair Value of $199.63 (OVERVALUED)

Still, Illumina faces meaningful risks if export restrictions in China tighten further or if research funding and clinical demand soften and undercut those margin and growth assumptions.

Find out about the key risks to this Illumina narrative.

Another View on Illumina's Valuation

While the narrative fair value for Illumina centers on $199.63 using earnings assumptions, the SWS DCF model points to a future cash flow value of $257.70 with the stock trading at $245.18. That frames Illumina as modestly undervalued on this lens. Which perspective do you think better reflects the risks and execution hurdles ahead?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 29 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the cross currents around Illumina feel mixed, that is exactly why it helps to move fast and test the numbers yourself against your own expectations. You can weigh both the concerns and the potential by reviewing the 2 key rewards and 3 important warning signs.

Looking for more Illumina investment ideas?

If Illumina has sharpened your focus on opportunity, do not stop here. Broader idea flow matters. Missing the next setup can affect returns.

• Target powerful upside skew by scanning hand picked small caps in the 7 elite penny stocks with strong financials before they get crowded.
• Zero in on quality at a discount by filtering for financially strong companies in the 29 high quality undervalued stocks that still trade below intrinsic worth estimates.
• Prioritise staying power by reviewing the 30 resilient stocks with low risk scores and focus on businesses with resilient profiles when markets turn choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com